PD42-06 EFFECTS OF INTRAVESICAL BOTULINUM TOXIN TYPE-A INJECTION LOCATION ON SYMPTOM SCORES AND SEXUAL FUNCTIONS IN FEMALE PATIENTS WITH A DIAGNOSIS OF REFRACTORY BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS: A RANDOMIZED, PROSPECTIVE STUDY

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD42-06 EFFECTS OF INTRAVESICAL BOTULINUM TOXIN TYPE-A INJECTION LOCATION ON SYMPTOM SCORES AND SEXUAL FUNCTIONS IN FEMALE PATIENTS WITH A DIAGNOSIS OF REFRACTORY BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS: A RANDOMIZED, PROSPECTIVE STUDY Murat Karaburun, Eralp Kubilay, Derya Gökmen, Mehmet İlker Gökçe, Evren Süer, and Ömer Gülpınar Murat KaraburunMurat Karaburun More articles by this author , Eralp KubilayEralp Kubilay More articles by this author , Derya GökmenDerya Gökmen More articles by this author , Mehmet İlker GökçeMehmet İlker Gökçe More articles by this author , Evren SüerEvren Süer More articles by this author , and Ömer GülpınarÖmer Gülpınar More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003352.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To determine the effect of Intravesical Botulinum Toxin type-A (BTX-A) treatment with trigon included and trigone sparing on symptoms and sexual function in female patients diagnosed with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) who did not benefit from conventional treatments. METHODS: Patients with BPS/IC who were treated with hydrodistension+BTX-A were enrolled in the study between January 2020 and April 2022. Using the stratified randomization technique, patients were randomly randomized to one of two groups: hydrodistension+trigone sparing injection (Group-1) or hydrodistension+trigone-included injection (Group-2). The study comprised a total of 27 patients. The patients were evaluated with VAS, ICSI, ICPI, FSFI questionnaires, and 3-day voiding diaries, voiding tests, and residual urine tests (uroflowmetry and residue determination) in the preoperative period and in the postoperative first and third months. RESULTS: The study comprised a total of 27 patients, 14 from Group-1 with a mean age of 40,9 (±9,25) and 13 from Group-2 with a mean age of 41.7 (±10.3). Preoperative VAS, ICSI, ICPI, and FSFI scores for 27 patients were 8.95±1.39; 16.21±2.94; 14.38±2.27 and 15.92±3.73, respectively. VAS, ICSI, ICPI, and FSFI scores were 3.47±2.94; 7.14±3.97; 6.47±3.95 and 22.41±5.02 at the first postoperative month, respectively. It was 2.69±3.18; 5.79±5.08; 5.79±4.95 and 24.41±6.06 in the third month postoperatively. Treatment led to statistically significant improvements in all four variables (p<0.001). While significant improvement was observed with treatment in both groups, no difference was found between the two groups in terms of treatment results (p: 0.89; p: 0.341; p: 0.488 and p: 0.706, respectively). In total, two patients had urinary tract infection in the postoperative period and one patient had retention, but there was no difference between the two groups in terms of adverse effects (p>0.05). CONCLUSIONS: Intravesical BTX-A treatment is an effective and safe treatment in female patients with BPS/IC unresponsive to conventional treatments. The treatment also contributes positively to sexual functions. The inclusion of trigone in the injections makes no difference to the treatment response. Source of Funding: none © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1113 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Murat Karaburun More articles by this author Eralp Kubilay More articles by this author Derya Gökmen More articles by this author Mehmet İlker Gökçe More articles by this author Evren Süer More articles by this author Ömer Gülpınar More articles by this author Expand All Advertisement PDF downloadLoading ...